AeroRx Therapeutics raises $21 million in Series A financing led by Avalon BioVentures to advance AERO-007 for COPD.

Oct 07, 2025•2 months ago

Amount Raised

$21 Million

Round Type

series a

La JollaBiotechnologyHealth Care

Investors

Alexandria Venture InvestmentsCorrelation VenturesAvalon Bio Ventures

Description

AeroRx Therapeutics announced a $21 million Series A financing led by Avalon BioVentures, with participation from Correlation Ventures and Alexandria Venture Investments. The funds will support late-stage clinical development of AERO-007, a potential first-line treatment for COPD. Data from a Phase 2a study showed AERO-007 was well tolerated and provided sustained bronchodilation. This financing positions AeroRx to advance toward a Phase 2b dose-optimization study.

Company Information

Company

AeroRx Therapeutics

Location

La Jolla, California, United States

About

AeroRx Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary nebulized combination therapies for chronic respiratory diseases. Their lead candidate, inhaled AERO-007, is a novel nebulized LABA/LAMA treatment for chronic obstructive pulmonary disease (COPD). The company aims to improve patient adherence and outcomes by providing an alternative to traditional inhalers.

Related People

1 contact

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends